Drug Combinations for Visceral Leishmaniasis
PURPOSE OF REVIEW: Several attempts have been made to combine drugs for treating visceral leishmaniasis, but only recently have effective drugs become available and combinations been tested systematically. RECENT FINDINGS: Sequential treatments with liposomal amphotericin B followed by miltefosine or paromomycin (as short as 7 days), as well as the concomitant administration of miltefosine and paromomycin (for 10 days) are very effective in India (>95%). Sodium stibogluconate plus paromomycin for 17 days is more than 90% effective in East Africa. The shortened combination regimens are cost-effective in India. No combination has been tested so far in Brazil, Nepal and Bangladesh, although studies may be expected in the near future. No cost-effectiveness analysis has been done as yet outside India. SUMMARY: There is evidence of high efficacy and benefits with sequential and co-administration treatments in India. More studies are needed in other endemic areas. Introducing combinations and scaling up their use will be challenging. Experience acquired with malaria may be useful. Proper monitoring of use and effects (efficacy and safety) will be required. Currently there are no options for fixed-dose combination treatments for leishmaniasis.
Main Author: | |
---|---|
Format: | Journal Article biblioteca |
Language: | EN |
Published: |
2010
|
Subjects: | Amphotericin B, Antimony Sodium Gluconate, Antiprotozoal Agents, Cost-Benefit Analysis, Drug Resistance, Combination Drug Therapy, Drug Toxicity, Visceral Leishmaniasis, Paromomycin, Phosphorylcholine, use, |
Online Access: | http://hdl.handle.net/10986/5120 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-okr-109865120 |
---|---|
record_format |
koha |
spelling |
dig-okr-1098651202021-04-23T14:02:21Z Drug Combinations for Visceral Leishmaniasis Olliaro, P. L. Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use PURPOSE OF REVIEW: Several attempts have been made to combine drugs for treating visceral leishmaniasis, but only recently have effective drugs become available and combinations been tested systematically. RECENT FINDINGS: Sequential treatments with liposomal amphotericin B followed by miltefosine or paromomycin (as short as 7 days), as well as the concomitant administration of miltefosine and paromomycin (for 10 days) are very effective in India (>95%). Sodium stibogluconate plus paromomycin for 17 days is more than 90% effective in East Africa. The shortened combination regimens are cost-effective in India. No combination has been tested so far in Brazil, Nepal and Bangladesh, although studies may be expected in the near future. No cost-effectiveness analysis has been done as yet outside India. SUMMARY: There is evidence of high efficacy and benefits with sequential and co-administration treatments in India. More studies are needed in other endemic areas. Introducing combinations and scaling up their use will be challenging. Experience acquired with malaria may be useful. Proper monitoring of use and effects (efficacy and safety) will be required. Currently there are no options for fixed-dose combination treatments for leishmaniasis. 2012-03-30T07:31:24Z 2012-03-30T07:31:24Z 2010 Journal Article Curr Opin Infect Dis 1535-3877 (Electronic) 0951-7375 (Linking) http://hdl.handle.net/10986/5120 EN http://creativecommons.org/licenses/by-nc-nd/3.0/igo World Bank Journal Article |
institution |
Banco Mundial |
collection |
DSpace |
country |
Estados Unidos |
countrycode |
US |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-okr |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Biblioteca del Banco Mundial |
language |
EN |
topic |
Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use |
spellingShingle |
Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use Olliaro, P. L. Drug Combinations for Visceral Leishmaniasis |
description |
PURPOSE OF REVIEW: Several attempts have been made to combine drugs for treating visceral leishmaniasis, but only recently have effective drugs become available and combinations been tested systematically. RECENT FINDINGS: Sequential treatments with liposomal amphotericin B followed by miltefosine or paromomycin (as short as 7 days), as well as the concomitant administration of miltefosine and paromomycin (for 10 days) are very effective in India (>95%). Sodium stibogluconate plus paromomycin for 17 days is more than 90% effective in East Africa. The shortened combination regimens are cost-effective in India. No combination has been tested so far in Brazil, Nepal and Bangladesh, although studies may be expected in the near future. No cost-effectiveness analysis has been done as yet outside India. SUMMARY: There is evidence of high efficacy and benefits with sequential and co-administration treatments in India. More studies are needed in other endemic areas. Introducing combinations and scaling up their use will be challenging. Experience acquired with malaria may be useful. Proper monitoring of use and effects (efficacy and safety) will be required. Currently there are no options for fixed-dose combination treatments for leishmaniasis. |
format |
Journal Article |
topic_facet |
Amphotericin B Antimony Sodium Gluconate Antiprotozoal Agents Cost-Benefit Analysis Drug Resistance Combination Drug Therapy Drug Toxicity Visceral Leishmaniasis Paromomycin Phosphorylcholine use |
author |
Olliaro, P. L. |
author_facet |
Olliaro, P. L. |
author_sort |
Olliaro, P. L. |
title |
Drug Combinations for Visceral Leishmaniasis |
title_short |
Drug Combinations for Visceral Leishmaniasis |
title_full |
Drug Combinations for Visceral Leishmaniasis |
title_fullStr |
Drug Combinations for Visceral Leishmaniasis |
title_full_unstemmed |
Drug Combinations for Visceral Leishmaniasis |
title_sort |
drug combinations for visceral leishmaniasis |
publishDate |
2010 |
url |
http://hdl.handle.net/10986/5120 |
work_keys_str_mv |
AT olliaropl drugcombinationsforvisceralleishmaniasis |
_version_ |
1756571586611118080 |